A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer (TRAK-ER)

April 5, 2024 updated by: Royal Marsden NHS Foundation Trust

A Randomised Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

Detection of molecular relapse with circulating tumour DNA analysis can identify which patients with ER positive breast cancer are relapsing on adjuvant endocrine therapy. This trial will aim to demonstrate that palbociclib and fulvestrant, can defer or prevent relapse in patients with ctDNA detected molecular relapse.

The TRAK-ER trial will have two phases, a ctDNA surveillance phase and a randomised therapy trial in patients with positive ctDNA.

The TRAK-ER trial will establish a ctDNA screening programme for patients with ER positive breast cancer receiving adjuvant endocrine therapy with at least a further three years of standard adjuvant endocrine therapy planned. Patients recruited into the TRAK-ER study will have high-risk clinical features to identify patients at higher risk of future relapse.

ctDNA assays will be used to identify which people are at very high risk of relapse (i.e. those with a positive ctDNA result), and randomise this high risk population between standard endocrine therapy versus palbociclib plus fulvestrant for up to two years.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The TRAK-ER trial is a multi-centre, randomised, open-label trial in patients with early stage oestrogen reception positive (ER+) human epidermal growth receptor-2 negative (HER2-) breast cancer, whom have detectable circulating DNA (ctDNA) but no overt macroscopic disease on imaging. TRAK-ER aims to demonstrate that fulvestrant plus palbociclib improves relapse free survival compared to standard endocrine therapy in this patient group.

Despite current treatment, patients with ER+HER2- breast cancer are considered high-risk of distant recurrence for more than the first two decades after initial diagnosis. ctDNA analysis provides a non-invasive, serial source of tumour material which can monitor tumour dynamics and detect molecular relapse.

TRAK-ER will be split into two phases, the first surveillance phase aims to investigate the use of ctDNA to identify and predict the risk of molecular relapse in early ER+/HER2- breast cancer patients whom are receiving adjuvant endocrine therapy with no overt macroscopic disease on imaging. Using ctDNA assays, patients enrolled on TRAK-ER will receive ctDNA testing on a three-monthly basis for up to three years. In the instance where ctDNA is detected, imaging will determine whether overt disease is present. If a patient had a positive ctDNA detection and no macroscopic disease on the staging scan, the patient will be randomised to one of the treatment groups in the second phase of TRAK-ER, the treatment phase.

The treatment phase of TRAK-ER will be a randomised, open-label study which aims to determine whether fulvestrant plus palbociclib (intervention arm) improves relapse free survival compared to standard endocrine therapy (control arm) in patients carried through from the surveillance phase. Patients on each arm will receive treatment (fulvestrant plus palbociclib or standard endocrine therapy) for up to 24 months. Six monthly imaging will determine the presence of macroscopic disease. If macroscopic disease is observed, the patient will discontinue TRAK-ER treatment and commence standard therapy outside of the TRAK-ER trial.

Study Type

Interventional

Enrollment (Estimated)

1100

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Angers, France, 49055
      • Annecy, France, 90074
        • Recruiting
        • Centre Hospitalier Annecy Genevois_Site d'Annecy
        • Contact:
      • Avignon, France, 84000
        • Recruiting
        • Institut du Cancer Avignon Sainte Catherine
        • Contact:
      • Blois, France, 41016
        • Recruiting
        • Centre Hospitalier Simone Veil de Blois
        • Contact:
      • Bordeaux, France
      • Clermont Ferrand, France, 63011
      • Dijon, France, 21079
        • Recruiting
        • Centre George François Leclerc
        • Contact:
      • Grenoble, France, 38000
        • Recruiting
        • Groupe Hospitalier Mutualiste de Grenoble
        • Contact:
      • Limoges, France, 87042
      • Limoges, France, 87000
        • Recruiting
        • Clinique Chenieux
        • Contact:
      • Lyon, France, 69373
      • Marseille, France, 13273
      • Nantes, France, 44805
      • Nice, France, 06189
      • Paris, France, 94800
      • Paris, France
      • Reims, France, 51726
      • Rennes, France, 25042
      • Rouen, France, 76038
      • Toulouse, France, 31059
  • United Kingdom
      • Bournemouth, United Kingdom, BH7 7DW
        • Recruiting
        • University Hospitals Dorset: Royal Bournemouth Hospital
        • Contact:
      • Huntingdon, United Kingdom, PE29 6NT
        • Recruiting
        • North West Anglia NHS Foundation Trust: Hinchingbrooke Hospital
        • Contact:
      • Liverpool, United Kingdom
        • Recruiting
        • The Clatterbridge Cancer Centre NHS Foundation Trust
        • Contact:
      • London, United Kingdom, EC1A 7BE
        • Recruiting
        • Barts Health Nhs Trust
        • Contact:
      • London, United Kingdom, SW3 6JJ
        • Recruiting
        • The Royal Marsden NHS Foundation Trust
        • Contact:
        • Principal Investigator:
          • Nicholas Turner
      • London, United Kingdom, NW1 2BU
        • Recruiting
        • University College London Hospital
        • Contact:
      • London, United Kingdom, HA6 2RN
        • Recruiting
        • Mount Vernon Hospital
        • Contact:
      • Manchester, United Kingdom, M20 4BX
        • Recruiting
        • The Christie NHS Foundation Trust
        • Contact:
      • Nottingham, United Kingdom, NG5 1PB
        • Recruiting
        • Nottingham University Hopsitals NHS Trust
        • Contact:
      • Oxford, United Kingdom, OX3 7LE
        • Recruiting
        • Oxford Cancer & Haematology Centre, Churchill Hospital,
        • Contact:
      • Peterborough, United Kingdom, PE3 9GZ
        • Recruiting
        • North West Anglia NHS Foundation Trust: Peterborough Hospital
        • Contact:
      • Poole, United Kingdom, BH15 2JB
      • Sheffield, United Kingdom, S10 2SJ
        • Recruiting
        • Weston Park Hospital
        • Contact:
    • Cornwall
      • Truro, Cornwall, United Kingdom, TR1 3LJ
        • Recruiting
        • Royal Cornwall Hospitals NHS Trust
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria for ctDNA Surveillance:

  1. Written informed consent to participate in the trial and to donation of tissue and blood samples
  2. Male or female patients aged 18 years or older
  3. ECOG performance status 0, 1 or 2 (see https://ecog-acrin.org/resources/ecog-performance-status)
  4. Histologically proven primary ER+ (Allred score 6/8 or greater, or stain in ≥10% of cancer cells) and HER2- (immunohistochemistry 0/1+ and/or negative by in situ hybridization) breast cancer as determined by local laboratory

  5. Patients with high risk early stage breast cancer according to at least one of the following criteria:

    Primary surgery (no other treatment prior to surgery) A. Four or more involved axillary lymph nodes or positive supraclavicular lymph node at diagnosis, or

    B. Tumour size > 5 cm, regardless of lymph node status, or

    C. 1-3 involved axillary lymph nodes and at least one of the following; i) Tumour size > 3 cm, ii) histological grade 3 iii) high genomic risk defined as Oncotype Dx Recurrence Score >=26, Prosigna score >=60, EPclin risk score >=4.0, or Mammaprint high risk category, or

    D. At least a 15% predicted residual risk of death within 10 years using NHS PREDICT (see appendix A3 on calculating predicted residual risk of death with PREDICT)

    Neoadjuvant chemotherapy (chemotherapy prior to surgery) E. At least one lymph node positive (micrometastasis or macrometastasis) after chemotherapy F. Lymph node negative and tumour size > 3 cm after chemotherapy

    Neoadjuvant endocrine therapy (endocrine based therapy prior to surgery) Use the primary surgery criteria - staging tumour size and lymph node status may be either the pathological staging after endocrine therapy or on the initial clinical staging prior to neoadjuvant therapy

  6. Available tissue from one archival tumour tissue sample (either from diagnostic biopsy, primary surgery or where available residual disease post-neoadjuvant chemotherapy)

    i) Patients with bilateral tumours may enrol if both are ER+ and HER2- and if one archival tissue sample can be provided from each tumour

    ii) Patients with multifocal breast cancer whose histopathologically examined tumours all meet pathologic criteria for ER+ and HER2- breast cancer, and two archival tissue samples can be provided.

  7. No evidence of macroscopic distant metastatic disease or incurable locally advanced disease on staging scans conducted at any time since initial diagnosis.

  8. Patients receiving standard endocrine therapy with aromatase inhibitors (letrozole, anastrazole, exemestane), tamoxifen, or combination of such for a minimum of 6 months* and maximum of 7 years duration with an additional three years of endocrine therapy planned. Pre- or peri-menopausal patients may also receive GnRH analogues.

    * patients may enrol during the first 6 months of standard endocrine therapy, and wait until at least 6 months of endocrine therapy has been received prior to starting ctDNA surveillance

  9. Patients must have had surgery achieving clear margins (as per local guidelines)
  10. Female and male patients of reproductive potential must be willing to use an adequate method of contraception for the first three years of the trial, if randomised to standard endocrine therapy for the duration of trial treatment through to at least 4 weeks after the last dose of trial treatment, and if randomised to fulvestrant and palbociclib to 2 years after the last dose of fulvestrant (see section 4.6). Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.
  11. Patients willing to have frequent blood tests.

Inclusion Criteria for Interventional phase:

  1. Signed informed consent for treatment
  2. ECOG performance status 0, 1 or 2
  3. Women of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  4. Female and male patients of childbearing potential must be willing to use an adequate method of contraception (section 4.6), starting with the first dose of treatment through 4 weeks after the last dose of treatment if randomised to standard endocrine therapy and 2 years after the last dose of fulvestrant if randomised to fulvestrant and palbociclib. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient. Female patients will be deemed not of childbearing potential if they are postmenopausal or have had irreversible sterilisation

  5. Patient has adequate bone marrow and organ function as defined by the following laboratory values:

    1. Absolute Neutrophil Count (ANC) ≥ 1.5 × 109/L
    2. Platelets ≥ 100 × 109/L
    3. Haemoglobin ≥ 100 g/L
    4. INR ≤1.5
    5. Creatinine <1.5 x ULN and creatinine clearance ≥30ml/min
    6. Total bilirubin < ULN except for patients with Gilbert's syndrome who may only be included if the total bilirubin is ≤ 3.0 × ULN or direct bilirubin ≤ 1.5 × ULN.
    7. Alanine aminotransferase (ALT) < 2.5 x ULN
    8. Aspartate aminotransferase (AST) < 2.5 × ULN
  6. Patients must be post-menopausal OR Pre- or peri-menopausal patients or men may be enrolled if they have ovarian suppression with the GnRH analogue goserelin or similar GnRH analogue. Patients must have commenced goserelin or an alternative GnRH analogue at least 2 weeks prior to Cycle 1 Day 1 and continue throughout the study if randomised to fulvestrant and palbociclib.

Post-menopausal female patients, as defined by at least one of the following:

  • Age ≥60 years;
  • Age <60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause, and serum estradiol and FSH levels within the institutional laboratory's reference range for post-menopausal females;
  • Documented bilateral oophorectomy;

Exclusion Criteria for ctDNA Surveillance:

  1. Any concurrent or planned treatment for the current diagnosis of breast cancer other than adjuvant endocrine therapy or a bisphosphonate.
  2. Patients with prior exposure to a CDK 4/6 inhibitor as part of standard of care may enrol only after at least 12 months from completing CDK4/6 therapy.
  3. Prior exposure to fulvestrant is not permitted.
  4. Prior diagnosis of cancer including prior diagnosis of breast cancer in the previous 5 years, other than for non-melanoma carcinoma of the skin or cervical carcinoma in situ
  5. Patients previously entered into a therapeutic trial where experimental therapy is continued post-surgery. Patients who have entered a clinical trial of a CDK4/6 inhibitor in the adjuvant setting are not eligible. Patients who received a CDK4/6 inhibitor only before an operation, with no post-operative adjuvant use, are eligible.
  6. Treatment with an unlicensed or investigational product within 4 weeks prior registration to trial
  7. Patient has not recovered to ≤ grade 1 (except alopecia or certain other toxicities, which in the opinion of the Investigator should not exclude the patient) from related side effects of any prior antineoplastic therapy, not including side-effects of endocrine therapy
  8. Patient with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral medication (e.g. Crohn's disease, ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome, or small bowel resection)
  9. Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator' opinion cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol.

  10. Clinically significant uncontrolled heart disease including any of the following:

    1. History of myocardial infarction (MI), angina pectoris, symptomatic pericarditis, or coronary artery bypass graft (CABG) within 6 months prior to trial entry
    2. Symptomatic congestive heart failure
    3. Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome.
    4. Cardiac arrhythmia.
  11. History of pneumonitis, interstitial lung disease or pulmonary fibrosis
  12. Known history of Human Immunodeficiency Virus (HIV) (testing not required as part of study screening)
  13. Known active Hepatitis B or Hepatitis C (testing not required as part of study screening)
  14. Females who are known to be pregnant or breastfeeding
  15. History of bleeding diathesis (i.e. disseminated intravascular coagulation, clotting factor deficiency), other known abnormalities in coagulation or treatment with anticoagulants. Low molecular weight heparin (LMWH), low dose aspirin or clopidogrel are permitted.
  16. Child-Pugh class C hepatic impairment or creatinine clearance < 30ml/min.

Exclusion Criteria for Interventional phase:

  1. Evidence of recurrent disease (metastatic or local, see section 6.6 for management of patients with potentially curable local recurrences) on staging scans conducted since positive ctDNA result
  2. Known hypersensitivity to the excipients of palbociclib plus fulvestrant
  3. Any anti-cancer treatment since enrolling in the TRAK-ER study other than hormonal therapy or a bisphosphonate. Prior exposure to fulvestrant is not permitted.
  4. Diagnosis of an alternative cancer since enrolment in the trial other than non-melanoma cancer of the skin or cervical carcinoma in situ
  5. Patient has had major surgery within 4 weeks prior to starting trial treatment or has not recovered from major side effects of such procedure
  6. Patient is currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH), rivoroxiban or fondaparinux is allowed
  7. Patient has not recovered to ≤ grade 1 (except alopecia or certain other toxicities, which in the opinion of the Investigator should not exclude the patient) from related side effects of any prior antineoplastic therapy, not including side-effects of endocrine therapy
  8. Patient with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral medication (e.g. Crohn's disease, ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome, or small bowel resection)
  9. Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator' opinion cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol.

  10. Clinically significant uncontrolled heart disease including any of the following:

    1. History of myocardial infarction (MI), angina pectoris, symptomatic pericarditis, or coronary artery bypass graft (CABG) within 6 months prior to trial entry
    2. Symptomatic congestive heart failure
    3. Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome.
    4. Cardiac arrhythmia.

  11. Patient is currently receiving any of the following substances and cannot be discontinued 7 days prior to Cycle 1 Day 1:

    • Medications that are strong inducers or inhibitors of CYP3A4 (section 8.5.2)
    • Herbal preparations/medications, dietary supplements, fruits (e.g grapefruit, pomelos, starfruit, Seville oranges) and their juice
  12. History of pneumonitis, interstitial lung disease or pulmonary fibrosis
  13. Known history of HIV (testing not required as part of study screening)
  14. Known active Hepatitis B or Hepatitis C (testing not required as part of study screening)
  15. Patient has a history of non-compliance to medical regimen
  16. History of bleeding diathesis (i.e. disseminated intravascular coagulation, clotting factor deficiency), other known abnormalities in coagulation or treatment with anticoagulants. Low molecular weight heparin (LMWH), low dose aspirin or clopidogrel are permitted.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Standard endocrine therapy

Standard endocrine therapy will continue for up to 24 months on trial.

Standard endocrine therapies include tamoxifen, and aromatase inhibitors (letrozole, anastrazole, exemestane).
Drug: Tamoxifen
As per clinical guidelines
Drug: Letrozole
As per clinical guidelines
Drug: Exemestane
As per clinical guidelines
Drug: Anastrozole
As per clinical guidelines
Experimental: Palbociclib and fulvestrant

Treatment with palbociclib plus fulvestrant will continue for a maximum of 24 months.

Palbociclib will be given orally once a day on days 1-21 of each 28 day cycle.

Fulvestrant 500 mg will be administered on cycle 1 days 1 and 15, cycle 2 day 1 and then every 28 days thereafter (plus or minus 3 days) as two intramuscular injections of 250mg fulvestrant at each visit.
Drug: Palbociclib 125Mg Tab
Palbociclib Tablets, 125 mg orally once daily, beginning on Cycle 1, on Days 1-21 of each 28-day cycle.
Drug: Fulvestrant injection
Fulvestrant Intramuscular injections, 500 mg as two injection of 250mg fulvestrant in 5ml solution at each visit. No fulvestrant dose reductions are permitted. Administered on days 1, 15 (plus or minus 3 days), 29 (plus or minus 3 days), and every 28 (plus or minus 3 days) days thereafter.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of positive ctDNA result during surveillance (Surveillance phase)
Time Frame: Up to 36 months from entry to study
Test during the surveillance phase detects presence of ctDNA
Up to 36 months from entry to study
Incidence of positive ctDNA result at first test (Surveillance phase)
Time Frame: Start of study
Test during the surveillance phase detects presence of ctDNA in the first test
Start of study
Relapse free survival (Treatment phase)
Time Frame: 60 months from randomisation
Time from randomization to invasive local/regional recurrence (including ipsilateral invasive breast recurrence) or distant recurrence or death from any cause. Patients with second primary invasive cancers (breast or non-breast) would be censored at time of detection.
60 months from randomisation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency and Severity of adverse events
Time Frame: up to 24 months from randomisation
Frequency and severity of Adverse Events (AEs) assessed as per CTCAE v5
up to 24 months from randomisation
Overall survival
Time Frame: up to 60 months from randomisation
Time from randomisation to death from any cause
up to 60 months from randomisation
Invasive disease free survival
Time Frame: up to 60 months from randomisation
Time from randomisation to invasive local/regional recurrence (including ipsilateral invasive breast recurrence), new breast cancer (ipsilateral or contralateral) or distant recurrence or death from any cause. Patients with non-invasive recurrences or second primary invasive cancers (non-breast) would be censored at time of detection.
up to 60 months from randomisation
Distant recurrence free survival
Time Frame: up to 60 months from randomisation
Time from randomization to distant invasive breast cancer recurrence or death from any cause. Patients with new contralateral invasive breast cancers or second primary invasive non-breast cancers would be censored at time of detection.
up to 60 months from randomisation
EQ-5D-5L quality of life assessment: Mobility element
Time Frame: up to 24 months from randomisation
Assessed using the 5-point scale.
up to 24 months from randomisation
EQ-5D-5L quality of life assessment: Self-care element
Time Frame: up to 24 months from randomisation
Assessed using the 5-point scale.
up to 24 months from randomisation
EQ-5D-5L quality of life assessment: Usual activities element
Time Frame: up to 24 months from randomisation
Assessed using the 5-point scale.
up to 24 months from randomisation
EQ-5D-5L quality of life assessment: Pain/ Discomfort element
Time Frame: up to 24 months from randomisation
Assessed using the 5-point scale.
up to 24 months from randomisation
EQ-5D-5L quality of life assessment: Anxiety/ Depression element
Time Frame: up to 24 months from randomisation
Assessed using the 5-point scale.
up to 24 months from randomisation
EQ-5D-5L quality of life assessment: Visual Analogue Scale
Time Frame: up to 24 months from randomisation
Assessed using 0-100 scale.
up to 24 months from randomisation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Royal Marsden NHS Foundation Trust

Collaborators

Pfizer
AstraZeneca
Institute of Cancer Research, United Kingdom
UNICANCER
Gustave Roussy, Cancer Campus, Grand Paris
Invitae Corporation

Investigators

  • Principal Investigator: Nicholas Turner, Royal Marsden NHS Foundation Trust

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 30, 2022

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

September 1, 2030

Study Registration Dates

First Submitted

June 25, 2021

First Submitted That Met QC Criteria

July 30, 2021

First Posted (Actual)

August 2, 2021

Study Record Updates

Last Update Posted (Actual)

April 8, 2024

Last Update Submitted That Met QC Criteria

April 5, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CCR5316

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HER2-negative Breast Cancer

Clinical Trials on Tamoxifen

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe